Fibrodysplasia Ossificans Progressiva: Literature Review and Case Report

Background. Fibrodysplasia ossificans progressiva (FOP) is a genetic disease of the heterotopic ossification group associated with the mutation in ACVR1/ALK2 gene. FOP is characterized by progressive heterotopic endochondral ossification of connective tissue that occurs in postnatal period. It leads to formation of qualitatively normal bone in extraskeletal areas. Congenital hallux deformity   is typical for this disease. The clinical picture is characterized by aggravations that are usually caused by trauma or viral infections. Formation of Heterotopic ossificate formation can be observed during aggravations. There is no etiological treatment for FOP. Systemic glucocorticosteroids, non-steroidal anti-inflammatory drug (NSAIDs), mast cell stabilisers, antileukotriene drugs and bisphosphonates can be used in these patients.

Clinical case description. The child was born with congenital hallux deformity typical for FOP. The disease onset was noted at the age of 2 years 8 months with a tumor-like painful mass on the neck. Oncological (lymphoproliferative) disease was suspected but biopsy from the lesion did not confirm its malignant nature. The child was consulted by pediatric rheumatologist who has diagnosed FOP. Etanercept and zoledronic acid were administrated, though etanercept was later discontinued. For now, the child receives zoledronic acid infusions 2 times per year and daily NSAIDs.

Conclusion. The difficulties in FOP diagnosing are associated to its sporadic nature and clinical picture similarity to other diseases. Suspected malignancy leads to biopsy that is highly undesirable in FOP patients due to high risk of iatrogenic complications.

1. Pignolo R, Shore E, Kaplan F. Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects. Orphanet J Rare Dis. 2011; 6(1):80. doi: https://doi.org/10.1186/1750-1172-6-80

2. Miao J, Zhang C, Wu S, et al. Genetic abnormalities in Fibrodysplasia Ossificans Progressiva. Genes Genet Syst. 2012; 87(4):213–219. doi: https://doi.org/10.1266/ggs.87.213

3. Palhares D, Leme L. Miosite ossificante progressiva: uma perspectiva no controle da doença. J Pediatr (Rio J). 2001;77(5): 431–434. doi: https://doi.org/10.2223/jped.287

4. Rothschild B, Martin L, Timm R. A new spontaneous model of fibrodysplasia ossificans progressiva. Brazilian Geographical Journal: Geosciences and Humanities Research Medium. 2010;1(2): 228–237.

5. Delai PLR, Kantanie S, Santili C, et al. Fibrodisplasia ossificante progressiva: uma doença heredit_aria de interesse multidisciplinar. Rev Bras Ortop. 2004;39(5).

6. Araújo Júnior C, Carvalho T, Costa M, et al. Fibrodisplasia ossificante progressiva: relato de caso e achados radiográficos. Radiol Bras. 2005;38:69–73; doi: https://doi.org/10.1590/s0100-39842005000100014

7. Kartal-Kaess M, Shore E, Xu M, et al. Fibrodysplasia ossificans progressiva (FOP): watch the great toes! Eur J Pediatr 2010;169(11):1417–1421. doi: https://doi.org/10.1007/s00431010-1232-5

8. Shehab D, Elgazzar A, Collier B. Heterotopic ossification. J Nucl Med. 2002;43(3):346–353.

9. Kovalenko-Klychkova NA, Klychkova IY, Kenis VM, Melchenko EV. Fibrodysplasia ossificans progressiva in children (review and clinical analysis of 5 case reports). Travmatologiya i ortopediya Rossii = Traumatology and Orthopedics of Russia. 2014;20(1):102–109. (In Russ). doi: https://doi.org/10.21823/2311-2905-51

10. Антелава О.А., Никишина И.П., Гусева И.А. и др. Прогрессирующая оссифицирующая фибродисплазия // РМЖ. — 2015. — Т. 23. — № 7. — С. 415–420. [Antelava OA, Nikishina IP, Guseva IA, et al. Progressiruyushchaya ossifitsiruyushchaya fibrodisplaziya. RMJ. 2015;23(7):415–420. (In Russ).]

11. Sevbitov AV, Danshina SD, Kuznetsova MYu, et al. ICON as a method of choice for injectable treatment of initial caries in patients wiht ossifying progressive fibrodysplasia: a clinical case. Journal of Dentistry. 2019;23(6):280–283. (In Russ).

12. Sevbitov AV, Danshina SD, Borisov VV, et al. Diagnosis of ossification using computedtomography methods in patients diagnosed with “fibrodysplasia ossifying progressive”. Journal of Volgograd State Medical University. 2021;(1):154–158.(In Russ). doi: https://doi.org/10.19163/1994-9480-2021-1(77)-154-158

13. Sferco A, Naser C, Robledo H, et al. Fibrodysplasia osificante progresiva: pautas para su reconocimiento. Arch Argent Pediatr. 2001;99(3):249–252.

14. Kaplan FS, Pignolo RJ, Glaser DL, Shore EM. The seventeenth annual report of the fibrodysplasia ossificans progressiva (FOP) collaborative project. 2008. Available online: https://d3n8a8pro7vhmx.cloudfront.net/ifopa/pages/340/attachments/original/1481844970/17ANNUAL_REPORT-17-Revised_4.17_FK.pdf. Accessed on December 04, 2022.

15. Shaikh N, Arif F. Fibrodysplasia ossificans progressiva. J Pak Med Assoc. 2011;61(4):397–399.

16. Kozlova SI, Demikova NS. Nasledstvennye sindromy i mediko-geneticheskoe konsul’tirovanie. Moscow: KMK; 2007. 448 s. (In Russ).

17. Kaplan FS, Le Merrer ML, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1): 191–205. doi: https://doi.org/10.1016/j.berh.2007.11.007

18. Chakkalakal S, Zhang D, Culbert A, et al. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res. 2012;27(8):1746–1756. doi: https://doi.org/10.1002/jbmr.1637

19. Mao L, Yano M, Kawao N, et al. Role of matrix metalloproteinase-10 in the BMP-2 inducing osteoblastic differentiation. Endocr J. 2013;60(12):1309–1319. doi: https://doi.org/10.1507/endocrj.ej13-0270

20. Giacopelli F, Cappato S, Tonachini L, et al. Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva. Orphanet J Rare Dis. 2013;8:145. doi: https://doi.org/10.1186/1750-1172-8-145

21. Mura M, Cappato S, Giacopelli F, et al. The Role of the 3'UTR Region in the Regulation of the ACVR1/Alk-2 Gene Expression. PLoS One. 2012;7(12):e50958. doi: https://doi.org/10.1371/journal.pone.0050958

22. Kaplan F, McCluskey W, Hahn G, et al. Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family. J Bone Joint Surg Am. 1993;75(8):1214–1220. doi: https://doi.org/10.2106/00004623-199308000-00011

23. Shore EM, Feldman GJ, Xu M, Kaplan FS. The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3(1):201–204

24. Martelli A, Santos A. Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Organogenesis. 2014;10(3): 303–311. doi: https://doi.org/10.4161/org.29206

25. Xiao Y, Xiang L, Shao J. Bone morphogenetic protein. Biochem Biophys Res Commun. 2007;362(3):550–553; doi: https://doi.org/10.1016/j.bbrc.2007.08.045

26. Kaplan F, Groppe J, Pignolo R, et al. Morphogen Receptor Genes and Metamorphogenes: Skeleton Keys to Metamorphosis. Ann N Y Acad Sci. 2007;1116(1):113–133. doi: https://doi.org/10.1196/annals.1402.039

27. Hughes F, Collyer J, Stanfield M, et al. The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology. 1995;136(6):2671–2677. doi: https://doi.org/10.1210/endo.136.6.7750491

28. Kaplan F, Fiori J, DE LA Peña LS, et al. Dysregulation of the BMP-4 Signaling Pathway in Fibrodysplasia Ossificans Progressiva. Ann N Y Acad Sci. 2006;1068(1):54–65. doi: https://doi.org/10.1196/annals.1346.008

29. Zhang D, Schwarz E, Rosier R, et al. ALK2 Functions as a BMP Type I Receptor and Induces Indian Hedgehog in Chondrocytes During Skeletal Development. J Bone Miner Res. 2003;18(9): 1593–1604. doi: https://doi.org/10.1359/jbmr.2003.18.9.1593

30. Moreira P, An Y, Santos A, Genari S. In vitro analysis of anionic collagen scaffolds for bone repair. J Biomed Mater Res. 2004; 71B(2):229–237. doi: https://doi.org/10.1002/jbm.b.30026

31. Kaplan F, Xu M, Glaser D, et al. Early Diagnosis of Fibrodysplasia Ossificans Progressiva. Pediatrics. 2008;121(5):e1295–e1300. doi: https://doi.org/10.1542/peds.2007-1980

32. Kaplan F, Chakkalakal S, Shore E. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Models Mech. 2012;5(6):756–762. doi: https://doi.org/10.1242/dmm.010280

33. Rocke DM, Zasloff M, Peeper J, et al. Ageand joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1994;(301):243–248.

34. Kitterman J, Kantanie S, Rocke D, Kaplan F. Iatrogenic Harm Caused by Diagnostic Errors in Fibrodysplasia Ossificans Progressiva. Pediatrics. 2005;116(5):e654–e661. doi: https://doi.org/10.1542/peds.2005-0469

35. Kaplan F, Glaser D, Shore E, et al. The Phenotype of Fibrodysplasia Ossificans Progressiva. Clin Rev Bone Miner Metab. 2005;3(3-4): 183–188. doi: https://doi.org/10.1385/bmm:3:3-4:183

36. Pignolo R, Suda R, Kaplan F. The fibrodysplasia ossificans progressiva lesion. Clinic Rev Bone Miner Metab. 2005;3(1): 195–200. doi: https://doi.org/10.1385/BMM:3:3-4:195

37. Schaffer A, Kaplan F, Tracy M, et al. Developmental Anomalies of the Cervical Spine in Patients With Fibrodysplasia Ossificans Progressiva Are Distinctly Different From Those in Patients With Klippel-Feil Syndrome. Spine. 2005;30(12):1379–1385. doi: https://doi.org/10.1097/01.brs.0000166619.22832.2c

38. Kaplan F, Strear C, Zasloff M. Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1994;(304):238–247.

39. Deirmengian G, Hebela N, O’Connell M, et al. Proximal Tibial Osteochondromas in Patients with Fibrodysplasia Ossificans Progressiva. J Bone Joint Surg. 2008;90(2):366–374. doi: https://doi.org/10.2106/jbjs.g.00774

40. Kaplan F, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2008;30(3):379–390. doi: https://doi.org/10.1002/humu.20868

41. Kaplan F, Glaser D. Thoracic Insufficiency Syndrome in Patients With Fibrodysplasia Ossificans Progressiva. Clin Rev Bone Miner Metab. 2005;3(3-4):213–216. doi: https://doi.org/10.1385/bmm:3:3-4:213

42. Levy C, Lash A, Janoff H, Kaplan F. Conductive Hearing Loss in Individuals with Fibrodysplasia Ossificans Progressiva. Am J Audiol. 1999;8(1):29–33. doi: https://doi.org/10.1044/1059-0889(1999/011)

43. Verma A, Aga P, Singh S, Singh R. The stone man disease: fibrodysplasia ossificans progressiva: imaging revisited. Case Reports. 2012;2012(jul25 1):bcr2012006422-bcr2012006422. doi: https://doi.org/10.1136/bcr-2012-006422

44. Al Kaissi A, Kenis V, Ben Ghachem M, et al. The Diversity of the Clinical Phenotypes in Patients With Fibrodysplasia Ossificans Progressiva. J Clin Med Res. 2016;8(3):246–253. doi: https://doi.org/10.14740/jocmr2465w

45. Herring J. Tachdjian’s pediatric orthopaedics. Elsevier; 2021.

46. Kaplan F, Al Mukaddam M, Brown M, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2019;1:1-111. https://www.ifopa.org/for_medical_professionals. Accessed on December 04, 2022.

47. Bastepe M, Jüppner H. Pseudohypoparathyroidism, Albright’s Hereditary Osteodystrophy, and Progressive Osseous Heteroplasia: Disorders Caused by Inactivating GNAS Mutations. In: Endocrinology: Adult and Pediatric. Elsevieh; 2016. pp. 1147–1159.e6. doi: https://doi.org/10.1016/b978-0-323-18907-1.00066-4

48. Adegbite N, Xu M, Kaplan F, et al. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS‐based heterotopic ossification. Am J Med Genet A. 2008;146A(14):1788–1796. doi: https://doi.org/10.1002/ajmg.a.32346

49. Pignolo R, Foley K. Nonhereditary Heterotopic Ossification: Implications for Injury, Arthropathy, and Aging. Clin Rev Bone Miner Metab. 2005;3(3-4):261–266. doi: https://doi.org/10.1385/bmm:3:3-4:261

50. Zaghloul K, Heuer G, Guttenberg M, et al. Lumbar puncture and surgical intervention in a child with undiagnosed fibrodysplasia ossificans progressiva. J Neurosurg Pediatr. 2008;1(1):91–94. doi: https://doi.org/10.3171/ped-08/01/091

51. Cappato S, Giacopelli F, Ravazzolo R, et al. The Horizon of a Therapy for Rare Genetic Diseases: A “Druggable” Future for Fibrodysplasia Ossificans Progressiva. Int J Mol Sci. 2018;19(4):989. doi: https://doi.org/10.3390/ijms19040989

52. Song H, Wang Q, Wen J, et al. ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a. Int J Mol Sci. 2012;13(2):2063–2077. doi: https://doi.org/10.3390/ijms13022063

53. Wentworth K, Masharani U, Hsiao E. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2019;85(6):1180–1187. doi: https://doi.org/10.1111/bcp.13823

54. Haviv R, Moshe V, De Benedetti F, et al. Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome? Pediatr Rheumatol. 2019;17(1):84. doi: https://doi.org/10.1186/s12969-019-0386-6

55. Eekhoff E, Netelenbos J, de Graaf P, et al. Flare-Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [18F]-NaF PET/CT Study and a Systematic Review. JBMR Plus. 2017;2(1):55–58. doi: https://doi.org/10.1002/jbm4.10008

56. Moore R, Dormans J, Drummond D, et al. Chin-on-Chest Deformity in Patients with Fibrodysplasia Ossificans Progressiva. J Bone Joint Surg Am. 2009;91(6):1497–1502. doi: https://doi.org/10.2106/jbjs.h.00554

57. Scarlett R, Rocke D, Kantanie S, et al. Influenza-like Viral Illnesses and Flare-ups of Fibrodysplasia Ossificans Progressiva. Clin Orthop Relat Res. 2004;(423):275–279. https://doi.org/10.1097/01.blo.0000129557.38803.26

58. Lanchoney T, Cohen R, Rocke D, et al. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr. 1995;126(5):762–764. doi: https://doi.org/10.1016/s0022-3476(95)70408-6

59. Luchetti W, Cohen R, Hahn G, et al. Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol. 1996;81(1):21–25. doi: https://doi.org/10.1016/s1079-2104(96)80141-7

60. Kaplan F, Zasloff M, Kitterman J, et al. Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva. J Bone Joint Surg Am. 2010;92(3):686–691. https://doi.org/10.2106/jbjs.i.00705

61. Solomon D, Wakjira I, Hailu D, Gorfy Y. Fibroplasia Ossificans Progressiva: A Case Report of a Rare Disease Entity. Ethiop J Health Sci. 2018;28(4):513–516. https://doi.org/10.4314/ejhs.v28i4.17

62. Shah ZA, Rausch S, Arif U, El Yafawi B. Fibrodysplasia ossificans progressiva (stone man syndrome): a case report. J Med Case Rep. 2019;13(1):364. https://doi.org/10.1186/s13256-019-2297-z

63. Aziz PAA, Panhwar IA. Fibrodysplasia Ossificans Progressiva in a 5-Year Boy. J Coll Physicians Surg Pak. 2019;29(11):1129–1130. doi: https://doi.org/10.29271/jcpsp.2019.11.1129

64. Garcia-Pinzas J, Wong JE, Fernández MA, Rojas-Espinoza MA. Fibrodysplasia ossificans progressiva: diagnosis in primary care. Rev Paul Pediatr. 2013;31(1):124–128. https://doi.org/10.1590/s0103-05822013000100020